Skip to content
TrialScanner

NCT04415073

A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19

Phase 2TerminatedSNDXLead

Registry record

Lead sponsor
Syndax Pharmaceuticals
Conditions
Coronavirus; COVID; ARDS; Cytokine Storm; Cytokine Release Syndrome
Primary completion
Jul 13, 2020Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04415073 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04415073: A Phase 2 Study to Evaluate... | TrialScanner